Generated September 14, 2026 at 8:31 PM ET
· Covers September 14 trading day
· 9 of 207 ready 8-Ks selected
· AI-assisted overview
The day's filings featured two FDA approvals: Scholar Rock's ISEMBYLD for spinal muscular atrophy and Biofrontera's Ameluz PDT for superficial basal cell carcinoma. M&A activity included Quince Therapeutics' asset sale to Ayma, Elmet Group's $450M investment from DoW, and Magnolia Oil & Gas closing its WildFire acquisition. CenterPoint Energy disclosed a cyber incident affecting customer data, while Cambium Networks announced a 53.6% workforce reduction and subsidiary administration. Summit Therapeutics reported positive overall survival data from its HARMONi-2 trial of ivonescimab, and Boxlight regained Nasdaq compliance after a PIPE.
QNCX
Quince Therapeutics, Inc.
M&A
negative
materiality 0.80
September 14, 2026, 4:30 PM ET
Quince Therapeutics sells A-T assets to Ayma for $450K; President Ryan departs
- Completed sale of Quince SpA, AIDE IP, and eDSP machines to Ayma Therapeutics for $450,000 cash on Sept 8, 2026.
- Sale includes ~55 AIDE/eDSP machines: ~20 at Italian facilities, ~35 at clinical trial sites.
- President Charles Ryan separated Sept 8, 2026; severance of $1,014,489.04 under Separation Agreement.
SRRK
Scholar Rock Holding Corp
regulatory
positive
materiality 1.00
September 14, 2026, 8:00 AM ET
FDA approves Scholar Rock's ISEMBYLD (apitegromab) for SMA in adults and children ≥2 years
- FDA approved ISEMBYLD (apitegromab-mstn) for SMA in adults/children ≥2 yrs on SMN2-targeted therapy.
- Phase 3 SAPPHIRE: 2.2-point HFMSE improvement vs placebo (nominal p=0.0121); 34.2% ≥3-point gain vs 13.5% (OR 3.8).
- Safety: fractures 9% ISEMBYLD vs 2% placebo; database >500, some treated >7 years.
M&A
positive
materiality 0.90
September 14, 2026, 4:30 PM ET
Elmet Group secures $450M DoW investment for tungsten expansion; $200M initial tranche closed
- DoW committed up to $450M: initial $200M for 200,000 Class A Preferred shares plus warrants; up to $250M in future tranches.
- Class A Preferred accrues 5.5% cumulative PIK dividends; ranks senior to common on liquidation.
- Penny Warrant covers 5,675,506 shares at $0.001; Strike Price Warrant covers 1,891,835 shares at $15.92.
MGY
Magnolia Oil & Gas Corp
M&A
positive
materiality 0.90
September 14, 2026, 4:10 PM ET
MGY closes WildFire acquisition for $2.57B cash, 32.2M shares, $600M notes
- Closed Sept 10, 2026; purchase price: $2,570M cash, 32,203,000 MGY shares, assumption of 7.5% $600M notes due 2029.
- WildFire H1 2026 (unaudited): revenue $642M, net income $102M; total assets $2.83B as of June 30, 2026.
- MGY assumed $600M 7.5% Senior Notes due 2029 via supplemental indenture; added Magnolia Midstream as guarantor to 2032/2034 notes.
regulatory
positive
materiality 0.90
September 14, 2026, 9:29 AM ET
FDA approves Biofrontera's Ameluz PDT for superficial basal cell carcinoma; launch expected Q4 2026–Q1 2027
- FDA approved sNDA for Ameluz (aminolevulinic acid) topical gel 10% + BF-RhodoLED lamp for sBCC in adults; first US PDT approved for skin cancer.
- Phase 3 trial (187 adults): composite complete response 66% (95/145) with Ameluz PDT vs 5% (2/42) placebo; histological clearance 76% vs 19%.
- Estimated US market: 540,000–720,000 sBCC cases/yr (approx. 15–20% of 3.6M BCC cases); existing AK indication retained.
regulatory
positive
materiality 0.75
September 14, 2026, 5:00 PM ET
Boxlight regains Nasdaq equity compliance; avoids delisting with $4.8M PIPE
- Panel granted continued listing after hearing on Aug 13, 2026; compliance with Equity Rule ($2.5M) restored.
- Closed $4.8M net from Series D preferred PIPE on Aug 5, 2026; total planned net proceeds ~$6.6M.
- Plans $15M equity line of credit and $2.9M debt-to-equity swap to bolster balance sheet.
CNP
CENTERPOINT ENERGY INC
cyber
negative
materiality 0.60
September 14, 2026, 5:15 PM ET
CenterPoint Energy discloses cyber incident exposing customer personal info
- In September 2026, a third-party claimed to have obtained a data set with some of the Company's customer information.
- Unauthorized party accessed personal info of a portion of customers through an external facing system; investigation ongoing.
- Electric and gas service deliveries remain operational and undisrupted by the Incident.
CMBMF
Cambium Networks Corp
other material
negative
materiality 0.90
September 14, 2026, 8:37 AM ET
Cambium Networks subsidiary enters administration; cuts 53.6% of workforce
- On Sept 14, 2026, Cambium Networks, Ltd (CNL) filed notice appointing RSM UK administrators; CNL group likely wound up.
- Sept 11, 2026: workforce reduced by 260 employees globally, or 53.6% of total workforce; no severance paid.
- SVP Products Vibhu Vivek terminated as role eliminated, effective Sept 11, 2026.
SMMT
Summit Therapeutics Inc.
other material
positive
materiality 0.90
September 14, 2026, 8:37 AM ET
Ivonescimab HARMONi-2 shows OS benefit: HR 0.73, median OS 30.8 vs 22.6 months vs pembrolizumab
- HARMONi-2 OS HR 0.73 (95% CI 0.57-0.95; p=0.009); median OS 30.8 vs 22.6 months.
- PD-L1 high subgroup HR 0.58; PD-L1 low HR 0.85; squamous HR 0.65; non-squamous HR 0.79.
- Serious TRAEs: 29.9% (ivonescimab) vs 21.6% (pembrolizumab); discontinuation 4.1% vs 5.0%.